XOMA Royalty (NASDAQ:XOMA) Sees Strong Trading Volume – Still a Buy?

XOMA Royalty Corporation (NASDAQ:XOMA) shares saw unusually-high trading volume on Monday . Approximately 342,730 shares changed hands during trading, an increase of 16% from the previous session’s volume of 295,767 shares.The stock last traded at $43.05 and had previously closed at $44.22.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on XOMA shares. HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a report on Thursday, April 30th. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Lucid Cap Mkts lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Finally, Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $53.75.

XOMA Royalty Trading Down 3.8%

The firm has a market cap of $533.28 million, a P/E ratio of 27.07 and a beta of 0.86. The business’s 50-day moving average is $42.14 and its two-hundred day moving average is $33.73. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The business had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. As a group, analysts expect that XOMA Royalty Corporation will post 0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

Several large investors have recently added to or reduced their stakes in XOMA. State of Alaska Department of Revenue acquired a new position in shares of XOMA Royalty during the fourth quarter valued at $27,000. Russell Investments Group Ltd. increased its holdings in shares of XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the period. JPMorgan Chase & Co. lifted its position in XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in XOMA Royalty in the 2nd quarter valued at about $116,000. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.